Co‐prescribing azathiopurine or 6‐mercaptopurine and 5‐aminosalicylate compounds in ulcerative colitisMayberry, H.1; Moshkovska, T. MD1; Mayberry, J. F. MD1*Inflammatory Bowel Diseases: February 2009 - Volume 15 - Issue 2 - p 190–192 doi: 10.1002/ibd.20750 Original Article Abstract Author Information Background:: A total of 254 senior consultant gastroenterologists with valid e‐mail addresses were identified from the membership list of the British Society of Gastroenterology (BSG) 2007. Methods:: They were sent by e‐mail a questionnaire which dealt with aspects of clinical practice and addressed cancer prevention in ulcerative colitis (UC). Replies were received from 97 clinicians (38% response rate). Results:: Ninety‐one (94%) advised patients with established UC to take 5‐aminosalicylate (5‐ASA) compounds for life. Seventy‐two of the 91 (79%) clinicians co‐prescribed 5‐ASA compounds with immune modulators for patients with UC. Only 3 clinicians advised patients to take folic acid as a daily supplement. A median of 20% (interquartile range 10%–50%) of their patients with UC were co‐prescribed a 5‐ASA compound and azathioprine or 6‐mercaptopurine. Of these, a median of 3.5% (interquartile 1%–5%) developed neutropenia. Conclustions:: Future research needs to be directed at the long‐term maintenance treatment and to address questions about which drugs should be used, in what combinations, and with what frequencies. 1 Department of Digestive Diseases, Leicester General Hospital, Leicester, United Kingdom * Department of Digestive Diseases, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK Email: email@example.com Received 22 July 2008; Accepted 5 August 2008 Published online 6 October 2008 in Wiley InterScience (www.interscience.wiley.com). © Crohn's & Colitis Foundation of America, Inc.